

**Anti-FOLR1 / FRA Reference Antibody (farletuzumab)
Recombinant Antibody
Catalog # APR10570****Specification**

Anti-FOLR1 / FRA Reference Antibody (farletuzumab) - Product Information

Application	FC, E, FTA
Primary Accession	P15328
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.36 KDa

Anti-FOLR1 / FRA Reference Antibody (farletuzumab) - Additional Information**Target/Specificity**

FOLR1 / FRA

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation

Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Storage

-80°C for 2 years under sterile conditions □ -20°C for 1 year under sterile conditions □ Avoid repeated freeze-thaw cycles.

Anti-FOLR1 / FRA Reference Antibody (farletuzumab) - Protein Information**Name** FOLR1**Synonyms** FOLR**Function**Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells (PubMed: [19074442](http://www.uniprot.org/citations/19074442), PubMed: [23851396](http://www.uniprot.org/citations/23851396), PubMed: [23934049](http://www.uniprot.org/citations/23934049), PubMed: [2527252](http://www.uniprot.org/citations/2527252)), PubMed: [19074442](http://www.uniprot.org/citations/19074442), PubMed: [23851396](http://www.uniprot.org/citations/23851396), PubMed: [23934049](http://www.uniprot.org/citations/23934049), PubMed: [2527252](http://www.uniprot.org/citations/2527252)

[8033114](http://www.uniprot.org/citations/8033114), PubMed:8567728). Has high affinity for folate and folic acid analogs at neutral pH (PubMed:23851396, PubMed:23934049, PubMed:2527252, PubMed:8033114, PubMed:8567728). Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release (PubMed:8567728). Required for normal embryonic development and normal cell proliferation (By similarity).

Cellular Location

Cell membrane; Lipid-anchor, GPI-anchor Apical cell membrane; Lipid-anchor, GPI- anchor Basolateral cell membrane; Lipid-anchor, GPI-like-anchor. Secreted Cytoplasmic vesicle. Cytoplasmic vesicle, clathrin-coated vesicle. Endosome. Note=Endocytosed into cytoplasmic vesicles and then recycled to the cell membrane

Tissue Location


Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.

Anti-FOLR1 / FRA Reference Antibody (farletuzumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-FOLR1 / FRA Reference Antibody (farletuzumab) - Images




Anti-FOLR1 / FRA Reference Antibody (farletuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-FOLR1 / FRA Reference Antibody (farletuzumab) is more than 95.5%, determined by SEC-HPLC.



Cyno FR α HEK293 cells were stained with Anti-FOLR1 / FRA Reference Antibody (farletuzumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC636=0.326 µg/mL



The endocytosis ratio farletuzumab by Human Fr α HEK 293 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 75% at antibody concentration of 55 ng/mL.